Back to today’s briefing

Story perspectives

New Cancer Treatment Targets KRAS, Promises Hopeful Outcomes

2/18/2025

25 5

Summary

Story summary

A groundbreaking cancer treatment breakthrough from UC San Francisco's Kevan Shokat targets the notorious KRAS protein, often found in various cancers. By merging the FDA-approved drug sotorasib with a radioactive antibody, this innovative approach seeks to obliterate tumors while reducing radiation exposure, offering new hope for improved patient outcomes.

1 of 1

Story summary

A groundbreaking cancer treatment breakthrough from UC San Francisco's Kevan Shokat targets the notorious KRAS protein, often found in various cancers. By merging the FDA-approved drug sotorasib with a radioactive antibody, this innovative approach seeks to obliterate tumors while reducing radiation exposure, offering new hope for improved patient outcomes.